Company news

electroCore, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

electroCore Announces Reverse Stock Split

February 13, 2023

electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update

January 16, 2023

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™

December 19, 2022

electroCore Announces Issuance of Two New U.S. Patents

December 6, 2022

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association

November 17, 2022

electroCore Announces Third Quarter 2022 Financial Results

November 2, 2022

electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC

October 31, 2022

electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers

October 31, 2022

electroCore to Announce Third Quarter 2022 Financial Results on November 3

October 26, 2022

electroCore Provides Select Third Quarter 2022 Financial Guidance

October 13, 2022

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

September 20, 2022

Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals

September 19, 2022

electroCore Announces Record Second Quarter 2022 Financial Results

August 3, 2022

electroCore to Announce Second Quarter 2022 Financial Results on August 4

July 27, 2022

electroCore Provides Select Second Quarter 2022 Financial Guidance

July 11, 2022

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome

July 6, 2022

electroCore Announces Listing Transfer to the Nasdaq Capital Market

June 22, 2022

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

May 23, 2022

electroCore Announces Record First Quarter 2022 Financial Results

May 4, 2022

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

April 20, 2022

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

April 11, 2022

electroCore Announces Exclusive License Agreement with Teijin for Japan Territory

April 4, 2022

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York

March 22, 2022

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results

March 9, 2022

electroCore Announces Changes to its Board of Directors

March 8, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

January 31, 2022

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022

January 24, 2022

electroCore Announces Shareholder Letter and Full-Year 2021 Business Update

January 17, 2022

gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)

January 11, 2022

electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store

January 10, 2022

electroCore Announces Publication of PREMIUM II Trial of gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

January 9, 2022

electroCore, Inc. Provides Update on Global Distribution Partners

December 15, 2021

electroCore, Inc. Announces The Launch of a New Online Shop in the United Kingdom

December 14, 2021

electroCore Announces New Patent for Stroke and TIA Treatment

December 12, 2021

electroCore Announces Third Quarter 2021 Financial Results

November 3, 2021

electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

October 20, 2021

electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England

October 19, 2021

electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

October 13, 2021

electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance

October 11, 2021

electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients

September 28, 2021

electroCore Announces Peter Cuneo as Board Chairman

September 19, 2021

electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices

September 14, 2021

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

September 13, 2021

electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.

August 23, 2021

electroCore Announces Second Quarter 2021 Financial Results

August 4, 2021

electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance

August 3, 2021

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

July 26, 2021

electroCore to Announce Second Quarter 2021 Financial Results on Thursday, August 5th

July 21, 2021

electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Neuroscience

July 18, 2021

electroCore Provides Business Update and Select Second Quarter 2021 Financial Guidance

July 12, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.